Should creep up to ten prior to PanC-DX release and double from there once these cancer cancer diagnostic products start to hit the market in late 2015. Great short-med-long term investment!
Time to buy and hold. Market cap 400k, subsidiary AST exploding, partnerships happening, low hanging fruit blooming... no debt, 30mil cash, multiple stem conferences next few months, clinical trial results for cartilage regen cosmetic surgery in 2015 and more clinical trials programs to start, BlacRock recently increased investments....dream investment!
Side note, icel/GE deal fell through, ICEL gave up on their ips ip and sold to Fujifilm of all companies.
2012 ICELL deal:
NEW YORK (GenomeWeb News) – GE Healthcare Life Sciences and Cellular Dynamics today announced a licensing deal allowing CDI to develop, manufacture, and sell cellular assays and models derived from induced pluripotent stem cells for drug discovery and toxicity screening.
2015 BTX deal:
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. (“ESI”) and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
Carolyn, since you are a newbie thought I'd let you know the buy and bash list includes jet pro, realtruf, baltbear and usually anyone who seriously converses with them. My advice to you is to put these ID's on 'ignore' since they will lie at all cost.
This is the result for companies who are first to jump into such a new and fast developing field. ICEL was in a sense lucky to brake even. Biotime on the other hand is slowly building their regen program based on a monopoly of hESC ip which is fast becoming the gold standard thanks to big data and genetic authentication.
GE partnership last month confirms this!
CUR, STEM, GERN, KOOL, CYTX, ASTM, ACTC, TNGN, BCLI..
All stem cell companies I know pale in comparison.
OncoCyte PanC patents to be confirmed, that will be huge factor. Technically genes can't be pAtented, but the proprietary gene marker method for testing can be. Once these patents come through all out buying blitz.
“The presentations on PanC-Dx™ at the AACR 2015 annual meeting will report on the first human clinical data from a key OncoCyte product development program,” said Joseph Wagner, PhD, OncoCyte’s Chief Executive Officer. “We, along with our clinical investigators, are pleased with the high sensitivity and specificity of PanC-Dx in diagnosing bladder cancer. The levels of accuracy that we report may give this new diagnostic the potential for widespread adoption as an improved method of detecting bladder cancer or its recurrence. We appreciate the effort of our clinical investigators and distinguished collaborators at Johns Hopkins University School of Medicine, leaders in bladder cancer research"
Those bash and buyers clowns have been using BTX as a chew toy for too long, later this year as we move above $10 and become more stable you will be seeing less of them guarenteed.